Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials

被引：17
作者：
Pan, Yangxun [1 ,2 ,3 ]
Wang, Ruojing [4 ]
Hu, Dandan [1 ,2 ]
Xie, Wa [1 ,2 ]
Fu, Yizhen [1 ,2 ]
Hou, Jiajie [1 ,2 ]
Xu, Li [1 ,2 ]
Zhang, Yaojun [1 ,2 ]
Chen, Minshan [1 ,2 ]
Zhou, Zhongguo [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[3] Karolinska Inst, Dept Oncol Pathol, S-17165 Solna, Sweden
[4] Sun Yat Sen Univ, Sun Yat Sen Univ Sch Nursing, Guangzhou 510080, Guangdong, Peoples R China
来源：
FRONTIERS IN BIOSCIENCE-LANDMARK | 2021年 / 26卷 / 10期
关键词：
Hepatocellular carcinoma; Molecular-targeted drugs; Immune checkpoint inhibitors; Hepatic arterial infu-sion chemotherapy; Combination therapy; Safety profiles; Efficacy; DOUBLE-BLIND; PHASE-III; SORAFENIB; THERAPY;
D O I：
10.52586/4994
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
10. Funding This work was funded by the National Natural Sci-ence Foundation of China (No. 81602143); Sun Yat-Sen University clinical medicine research 5010 program (No. KY050249).
引用
收藏
页码：873 / 881
页数：9
相关论文
共 25 条
[1]   Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study [J].
Bang, Yung-Jue ;
Kang, Yoon-Koo ;
Catenacci, Daniel V. ;
Muro, Kei ;
Fuchs, Charles S. ;
Geva, Ravit ;
Hara, Hiroki ;
Golan, Talia ;
Garrido, Marcelo ;
Jalal, Shadia I. ;
Borg, Christophe ;
Doi, Toshihiko ;
Yoon, Harry H. ;
Savage, Mary J. ;
Wang, Jiangdian ;
Dalal, Rita P. ;
Shah, Sukrut ;
Wainberg, Zev A. ;
Chung, Hyun Cheol .
GASTRIC CANCER, 2019, 22 (04) :828-837
[2]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[3]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[4]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[5]   Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma [J].
Fang, Jian-Hong ;
Xu, Li ;
Shang, Li-Ru ;
Pan, Chu-Zhi ;
Ding, Jin ;
Tang, Yun-Qiang ;
Liu, Hui ;
Liu, Chu-Xing ;
Zheng, Jia-Lin ;
Zhang, Yao-Jun ;
Zhou, Zhong-Guo ;
Xu, Jing ;
Zheng, Limin ;
Chen, Min-Shan ;
Zhuang, Shi-Mei .
HEPATOLOGY, 2019, 70 (03) :824-839
[6]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905
[7]   Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].
Finn, Richard S. ;
Ryoo, Baek-Yeol ;
Merle, Philippe ;
Kudo, Masatoshi ;
Bouattour, Mohamed ;
Lim, Ho Yeong ;
Breder, Valeriy ;
Edeline, Julien ;
Chao, Yee ;
Ogasawara, Sadahisa ;
Yau, Thomas ;
Garrido, Marcelo ;
Chan, Stephen L. ;
Knox, Jennifer ;
Daniele, Bruno ;
Ebbinghaus, Scot W. ;
Chen, Erluo ;
Siegel, Abby B. ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+
[8]   Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib [J].
Granito, Alessandro ;
Marinelli, Sara ;
Negrini, Giulia ;
Menetti, Saverio ;
Benevento, Francesca ;
Bolondi, Luigi .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (02) :240-249
[9]   Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial [J].
He, MinKe ;
Li, QiJiong ;
Zou, RuHai ;
Shen, JingXian ;
Fang, WanQiang ;
Tan, GuoSheng ;
Zhou, YuanMin ;
Wu, XiaoPing ;
Xu, Li ;
Wei, Wei ;
Le, Yong ;
Zhou, ZhongGuo ;
Zhao, Ming ;
Guo, Ying ;
Guo, RongPing ;
Chen, MinShan ;
Shi, Ming .
JAMA ONCOLOGY, 2019, 5 (07) :953-960
[10]   A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). [J].
Ikeda, Masafumi ;
Sung, Max W. ;
Kudo, Masatoshi ;
Kobayashi, Masahiro ;
Baron, Ari David ;
Finn, Richard S. ;
Kaneko, Shuichi ;
Zhu, Andrew X. ;
Kubota, Tomoki ;
Kraljevic, Silvija ;
Ishikawa, Kohei ;
Siegel, Abby B. ;
Kumada, Hiromitsu ;
Okusaka, Takuji .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
123